Kindex Therapeutics Industry-debut presentation at WBBA Life Science Innovation Northwest 2010. Created graphics and digital presentation.

2. Multi-Target Protein Kinase Modulators
derived from
Humulus Lupulus
‘Hops’

3. Certain statements made in this presentation are
forward-looking such as those, among others, relating
to the development, safety and efficacy of
therapeutic drugs and potential applications for
these products. The Company undertakes no
obligation to update the forward-looking statements
contained herein or to reflect events or
circumstances occurring after the date hereof

4. Company Highlights
Focus on pharmacophores with history of safe use
Target small molecules modulating key metabolic networks
Pre-clinical and clinical evidence supporting activity and safety
Initiating safety pharm/tox for IND in Type 2 Diabetes
Business Model: conduct Phase 1through 2a POC
clinical trials and seek a partner
4Q2009: $20M Series A investment by partner, Alticor

5. Background
Modified phytochemical extracts demonstrate selective protein
kinase modulation
1st Generation Product : R200 (Tetrahydro-iso-acids)
Mixture of 3 chemically distinct analogs
Potent anti-inflammatory activity
KDT500: most potent analog
Large patent portfolio protecting our position

6. Intellectual Property Portfolio
R200
>140 patents & applications worldwide
Methods of Treatment
Composition
Purification/Isolation Process
Indications
Diabetes/Metabolic Syndrome
Inflammation
Arthritis

7. 1st Generation Product:
Tetrahydro-iso- -acids Family (R200)
R= Isobutyl KDT500
R= sec-butyl
R= isopropyl

8. R200 Safety
Cell free In Vitro Animal Human
Multi-target selective Cytochrome p450 Extensive R200 Bioavailable in humans (orally
modulator Studies- IC50 (ug/ml) Toxicology studies absorbed within one hour &
-indicates CYP450 in animal models persists in serum for over 8
Gini Coefficient 2C9 is the route of hours)
calculation metabolism
demonstrates high Does not decrease
kinase specificity prostacyclin formation
indicating CV safety
No elevation of liver enzymes
No elevation of fecal
Calprotectin indicating
GI safety
Safe to GI system when orally
consumed at therapeutic
doses

9. Type 2 Diabetes Market
Approximately 90-95% of all diabetes cases in the U.S. are
Type 2
>20 million people in the U.S. currently have Type 2 Diabetes
Combined U.S. sales of glitazones alone in 2007 were
> $6.6 Billion

10. Unmet Needs in Diabetes
Therapeutic needs:
Multiple effects not achieved by single agent
(e.g. anti-hyperglycemic, anti-obesity,
hypertriglyceridemia)
Undesired side effects/patient compliance
Metformin: GI effects, lactic acidosis
Secretagogues: weight gain, hypoglycemia, tid dosing
Glitazones: weight gain, edema, liver safety
Insulin: injectable, hypoglycemia, weight gain

11. Diabetes
R200 comparable to Metformin
R200 Metformin
db/db Mouse Type 2
Diabetes model
Treatment:
100 mg/kg/ day
7 day treatment
Glucose Reduction Insulin Reduction
mg/ml ng/ml

12. R200 Prevents High Fat Diet Induced Obesity
HF
HF + R200
LF

13. Diet Shift
HF to HF HF + R200 to HF + R200
HF to HF + R200 HF + R200 to HF
HF to
HF+R200
Body weight (g)
HF+R200
to HF
weeks
pre post shift

14. R200 Reduces Fat Storage in Mice
on a Westernized High Fat Diet
HF to HF HF to HF+R200 HF+R200 to HF+R200 HF+R200 to HF
Liver Weight (g) Subcutaneous fat (g) Epididymal fat(g)

15. R200 Insulin Effects
HF LF HF+R200
Fasting Glucose p<0.05
p<0.01
Fasting Insulin p< 0.05
Insulin Sensitivity
in High Fat diet
induced Obesity
Mouse model

16. R200 Diabetes
Cell free In Vitro Animal Misc
Multi-target selective Stimulates the Improves insulin/ Demonstrated QSAR
kinase modulator secretion of GLP-1 glucose dynamics among various R200
in intestinal L-cells in animal model of analogs; KDT 500 most
Inhibits P70S6K kinase (NCI-H716) diabetes active
activity and protein
phosphorylation in Reduces inflammation/ Dramatically reduces
monocytes and glucose stimulated weight gain in high fat
macrophages adherence of mono- diet induced obesity
cytes to endothelial cells model
Non-competitive ATP
binding to kinases Improves insulin Produces weight /fat
Indicates allosteric sensitivity in 3T3L1 loss
modulation adipocytes in HF obese mice
Increases activity of Increases adipocyte Reduces fat
IGF1R receptor function in models of accumulation
Several fold lipid accumulation and in HF mice
adiponectin secretion
Increases activity of after inflammatory
AMPK stimulation

17. R200 Competitive Advantages
Multiple actions
Decrease insulin sensitivity, fasting glucose, and insulin
levels
Large impact on weight gain (in high fat rodent study)
Improves lipid values
Excellent safety profile in humans
Does not decrease prostacyclin formation in humans,
indicating CV safety
No elevation of liver enzymes in humans ingesting
therapeutic doses
No elevation of fecal calprotectin in humans ingesting
therapeutic doses indicating GI safety
Safe to GI system when orally consumed at therapeutic
doses
Orally Bioavailable

18. Product Pipeline
Discovery & Pre-clinical
IND Phase 1
Candidate Selection Development
KDT 500 (Type 2 Diabetes)
KDT 500 (Inflammation)
S
KDT 600 (Obesity)
New Candidates
Mid-shaded arrows illustrate pipeline through 1H2011

19. Development Plan
2010 cGMP manufacture of KDT500
FDA pre-IND meeting
Safety pharmacology and GLP toxicology
1H2011 IND submission
Initiate POC (Type 2 Diabetes)
in long-term canine and rodent studies
2H2011 Phase 1 SAD (in healthy subjects)
Phase 1 MAD (in healthy subjects)
1H2012 Phase 2a POC (in early diabetic subjects)

20. Experienced Management & Advisory Team
Jeffrey Bland, Ph.D. Metagenics, Healthcomm International
President and CEO Linus Pauling Institute
Matthew Tripp, Ph.D. Metagenics, Kellogg
Sr. V.P. R&D Phillip Morris Biotechnology
Neile Grayson, Ph.D. Sonus Pharmaceuticals, NeoRx
V.P. Drug Development Mallinckrodt, NIH
Lincoln Bouillon, MBA Metagenics
Business Manager Functional Medicine Res. Center
ActivX Biosciences, Merck Research
John Kozarich, Ph.D. Labs, Scripps Research Institute,
SAB Member Yale School of Medicine
Benjamin Cravatt, Ph.D. Scripps Research Institute
SAB Member
Paul Schimmel, Ph.D Scripps Research Institute, Sirtris,
Senior Advisor and Board Member Alnvlam, Repligen, Momenta, Cubist